U.S. markets close in 2 hours 23 minutes
  • S&P 500

    3,857.68
    -12.61 (-0.33%)
     
  • Dow 30

    31,527.64
    +136.12 (+0.43%)
     
  • Nasdaq

    13,162.12
    -196.66 (-1.47%)
     
  • Russell 2000

    2,248.55
    +17.04 (+0.76%)
     
  • Crude Oil

    61.73
    +1.98 (+3.31%)
     
  • Gold

    1,716.70
    -16.90 (-0.97%)
     
  • Silver

    26.41
    -0.47 (-1.74%)
     
  • EUR/USD

    1.2082
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.4650
    +0.0500 (+3.53%)
     
  • GBP/USD

    1.3984
    +0.0028 (+0.20%)
     
  • USD/JPY

    106.9200
    +0.2100 (+0.20%)
     
  • BTC-USD

    51,433.04
    +3,663.93 (+7.67%)
     
  • CMC Crypto 200

    1,029.59
    +41.49 (+4.20%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Recap: Cryolife Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Cryolife (NYSE:CRY) rose in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 81.82% over the past year to $0.20, which beat the estimate of $0.03.

Revenue of $67,896,000 decreased by 2.58% from the same period last year, which beat the estimate of $66,530,000.

Outlook

Cryolife hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Feb 11, 2021

View more earnings on CRY

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/kb8bhkpm

Recent Stock Performance

52-week high: $31.39

52-week low: $12.63

Price action over last quarter: Up 45.12%

Company Overview

Cryolife Inc is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures focused on aortic repair. The company has two reportable segments namely Medical devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue, On-X products, JOTEC products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular tissues. It generates a majority of its revenue from the Medical Devices segment. Geographically, the company generates a majority of its revenue from the United States.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.